TY - JOUR
AU1 - Larivée, Natasha
AU2 - Suissa, Samy
AU3 - Coulombe, Janie
AU4 - Tagalakis, Vicky
AU5 - Filion, Kristian
AB - Drug Saf (2017) 40:583–596 DOI 10.1007/s40264-017-0525-2 ORIGINAL RESEARCH ARTICLE Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First- Time Users and Restarters 1,2 1,2,3 1 1,4 • • • • Natasha Larive ´e Samy Suissa Janie Coulombe Vicky Tagalakis 1,2,3 Kristian B. Filion Published online: 5 April 2017 Springer International Publishing Switzerland 2017 Abstract scores were used to estimate hazard ratios (HRs) and 95% Introduction The effects of drospirenone-containing com- confidence intervals (CIs). bined oral contraceptives (COCs) on the risk of venous Results The final cohorts included 55,139 first-time users thromboembolism (VTE) remain controversial due to the (3582 drospirenone and 51,557 levonorgestrel) and 162,959 challenge in distinguishing between first-time users and restarters (23,191 drospirenone and 139,768 levonorgestrel). restarters, and their different underlying VTE risks, in The adjusted HR of VTE associated with drospirenone ver- healthcare databases. sus levonorgestrel was 3.19 (95% CI 1.12–9.08) for first-time Objectives The aim of this study was to describe the chal- users and 1.96 (95% CI 1.12–3.41) for restarters. lenge of studying the risk of VTE among first-time users of Conclusions We found an elevated risk of VTE associated drospirenone-containing COCs in a healthcare database and with 
TI - Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First-Time Users and Restarters
JF - Drug Safety
DO - 10.1007/s40264-017-0525-2
DA - 2017-04-05
UR - https://www.deepdyve.com/lp/springer-journals/drospirenone-containing-oral-contraceptive-pills-and-the-risk-of-GY0kfHdm02
SP - 583
EP - 596
VL - 40
IS - 7
DP - DeepDyve
ER -